
## **Richard G Frank**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7923938/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Prevalence and Treatment of Mental Disorders, 1990 to 2003. New England Journal of Medicine, 2005, 352, 2515-2523.	27.0	1,592
2	The impact of psychiatric disorders on work loss days. Psychological Medicine, 1997, 27, 861-873.	4.5	571
3	Promotion of Prescription Drugs to Consumers. New England Journal of Medicine, 2002, 346, 498-505.	27.0	384
4	What Is the Empirical Basis for Paying for Quality in Health Care?. Medical Care Research and Review, 2006, 63, 135-157.	2.1	271
5	Cost-effectiveness of Treatments for Major Depression in Primary Care Practice. Archives of General Psychiatry, 1998, 55, 645.	12.3	269
6	Behavioral Health Insurance Parity for Federal Employees. New England Journal of Medicine, 2006, 354, 1378-1386.	27.0	199
7	Addressing the Fentanyl Threat to Public Health. New England Journal of Medicine, 2017, 376, 605-607.	27.0	194
8	Measuring adverse selection in managed health care. Journal of Health Economics, 2000, 19, 829-854.	2.7	162
9	Can you get what you pay for? Pay-for-performance and the quality of healthcare providers. RAND Journal of Economics, 2010, 41, 64-91.	2.3	149
10	Medicaid And Mental Health: Be Careful What You Ask For. Health Affairs, 2003, 22, 101-113.	5.2	145
11	Effects of Pharmaceutical Promotion on Adherence to the Treatment Guidelines for Depression. Medical Care, 2004, 42, 1176-1185.	2.4	143
12	Risk Contracts in Managed Mental Health Care. Health Affairs, 1995, 14, 50-64.	5.2	117
13	Choice, price competition and complexity in markets for health insurance. Journal of Economic Behavior and Organization, 2009, 71, 550-562.	2.0	117
14	The Ongoing Regulation of Generic Drugs. New England Journal of Medicine, 2007, 357, 1993-1996.	27.0	112
15	Aligning Incentives in the Treatment of Depression in Primary Care With Evidence-Based Practice. Psychiatric Services, 2003, 54, 682-687.	2.0	111
16	Behavioral Health Parity and the Affordable Care Act. Journal of Social Work in Disability and Rehabilitation, 2014, 13, 31-43.	0.6	109
17	Prescription Drug Prices: Why Do Some Pay More Than Others Do?. Health Affairs, 2001, 20, 115-128.	5.2	94
18	Some Economics of Mental Health 'Carve-Outs'. Archives of General Psychiatry, 1996, 53, 933.	12.3	89

#	Article	IF	CITATIONS
19	Custom-made versus ready-to-wear treatments: Behavioral propensities in physicians' choices. Journal of Health Economics, 2007, 26, 1101-1127.	2.7	86
20	The medical treatment of depression, 1991–1996: productive inefficiency, expected outcome variations, and price indexes. Journal of Health Economics, 2002, 21, 373-396.	2.7	84
21	In Rural Areas, Buprenorphine Waiver Adoption Since 2017 Driven By Nurse Practitioners And Physician Assistants. Health Affairs, 2019, 38, 2048-2056.	5.2	78
22	The Value Of Mental Health Care At The System Level: The Case Of Treating Depression. Health Affairs, 1999, 18, 71-88.	5.2	75
23	The Politics And Economics Of Mental Health â€~Parity' Laws. Health Affairs, 1997, 16, 108-119.	5.2	65
24	Mental Health Policy and Psychotropic Drugs. Milbank Quarterly, 2005, 83, 271-298.	4.4	65
25	Banbury Forum Consensus Statement on the Path Forward for Digital Mental Health Treatment. Psychiatric Services, 2021, 72, 677-683.	2.0	65
26	Should Drug Prices Be Negotiated Under Part D Of Medicare? And If So, How?. Health Affairs, 2008, 27, 33-43.	5.2	64
27	The Effect of a Managed Behavioral Health Carve-Out on Quality of Carefor Medicaid Patients Diagnosed as Having Schizophrenia. Archives of General Psychiatry, 2004, 61, 442.	12.3	62
28	Managed Behavioral Health Care Carve-Outs: Past Performance and Future Prospects. Annual Review of Public Health, 2007, 28, 303-320.	17.4	59
29	Design Of Mental Health Benefits: Still Unequal After All These Years. Health Affairs, 2003, 22, 127-137.	5.2	58
30	Will Parity in Coverage Result in Better Mental Health Care?. New England Journal of Medicine, 2001, 345, 1701-1704.	27.0	51
31	Trends In Mental Health Cost Growth: An Expanded Role For Management?. Health Affairs, 2009, 28, 649-659.	5.2	49
32	The Costs Of Mental Health Parity: Still An Impediment?. Health Affairs, 2006, 25, 623-634.	5.2	48
33	Transforming Mental Health And Addiction Services. Health Affairs, 2021, 40, 226-234.	5.2	47
34	Impact of Alternative Interventions on Changes in Generic Dispensing Rates. Health Services Research, 2006, 41, 1876-1894.	2.0	45
35	Longâ€ŧerm Care Financing in the United States: Sources and Institutions. Applied Economic Perspectives and Policy, 2012, 34, 333-345.	5.6	44
36	A Model Mental Health Benefit in Private Health Insurance. Health Affairs, 1992, 11, 98-117.	5.2	42

#	Article	IF	CITATIONS
37	Therapies Offered at Residential Addiction Treatment Programs in the United States. JAMA - Journal of the American Medical Association, 2020, 324, 804.	7.4	41
38	Making the Opioid Public Health Emergency Effective. JAMA Psychiatry, 2018, 75, 767.	11.0	38
39	Changes In Mental Health Financing Since 1971: Implications For Policymakers And Patients. Health Affairs, 2006, 25, 601-613.	5.2	37
40	Regulation of Follow-on Biologics. New England Journal of Medicine, 2007, 357, 841-843.	27.0	36
41	The Impact of Nursing Home Payâ€forâ€Performance on Quality and Medicare Spending: Results from the Nursing Home Valueâ€Based Purchasing Demonstration. Health Services Research, 2017, 52, 1387-1408.	2.0	33
42	Behavioral Health Services for Women Who Have Breast Cancer. Journal of Clinical Oncology, 2009, 27, 706-712.	1.6	28
43	The Rise and Fall of Gabapentin for Bipolar Disorder. Medical Care, 2010, 48, 372-379.	2.4	28
44	What is the impact of policy differences on nursing home utilization? The cases of Germany and the Netherlands. Health Policy, 2015, 119, 814-820.	3.0	24
45	Impact of a Media Campaign for Disaster Mental Health Counseling in Post-September 11 New York. Psychiatric Services, 2006, 57, 1304-1308.	2.0	23
46	PRICING AND LOCATION OF PHYSICIAN SERVICES IN MENTAL HEALTH*. Economic Inquiry, 1985, 23, 115-133.	1.8	21
47	Passive Enrollment Of Dual-Eligible Beneficiaries Into Medicare And Medicaid Managed Care Has Not Met Expectations. Health Affairs, 2017, 36, 846-854.	5.2	21
48	Medication Use and Spending Trends Among Children With ADHD in Florida's Medicaid Program, 1996–2005. Psychiatric Services, 2012, 63, 115-121.	2.0	19
49	Dominated choices and Medicare Advantage enrollment. Journal of Economic Behavior and Organization, 2015, 119, 72-83.	2.0	19
50	Improving the Child Welfare System to Respond to the Needs of Substance-Exposed Infants. Hospital Pediatrics, 2019, 9, 651-654.	1.3	19
51	The impact of expanded Medicaid eligibility on access to naloxone. Addiction, 2019, 114, 1567-1574.	3.3	18
52	Parity for mental health and substance abuse care under managed care. , 1998, 1, 153-159.		17
53	Quality-constant "prices―for the ongoing treatment of schizophrenia: an exploratory study. Quarterly Review of Economics and Finance, 2004, 44, 390-409.	2.7	17
54	Health Insurance Exchanges — Making the Markets Work. New England Journal of Medicine, 2009, 361, 1135-1137.	27.0	16

#	Article	IF	CITATIONS
55	Enrollment in Medicare Advantage Plans in Miami-Dade County. Inquiry (United States), 2013, 50, 202-215.	0.9	16
56	Friction in the Path to Use of Biosimilar Drugs. New England Journal of Medicine, 2018, 378, 791-793.	27.0	16
57	The Creation of Medicare and Medicaid: The Emergence of Insurance and Markets for Mental Health Services. Psychiatric Services, 2000, 51, 465-468.	2.0	15
58	Risk adjustment of capitation payments to behavioral health care carve-outs: how well do existing methodologies account for psychiatric disability?. Health Care Management Science, 2000, 3, 159-169.	2.6	15
59	Prescription-Drug Prices. New England Journal of Medicine, 2004, 351, 1375-1377.	27.0	15
60	Paying for Early Interventions in Psychoses: A Three-Part Model. Psychiatric Services, 2015, 66, 677-679.	2.0	14
61	Financing Care of the Severely Mentally III: Incentives, Contracts, and Public Responsibility. Journal of Social Issues, 1989, 45, 131-144.	3.3	13
62	Using Elicitation Techniques to Estimate the Value of Ambulatory Treatments for Major Depression. Medical Decision Making, 2002, 22, 245-261.	2.4	13
63	Medicaid Expansion's Spillover to the Criminal Justice System: Evidence from Six Urban Counties. Rsf, 2020, 6, 244.	1.2	13
64	Factors Associated With High Levels Of Spending For Younger Dually Eligible Beneficiaries With Mental Disorders. Health Affairs, 2014, 33, 1006-1013.	5.2	12
65	Realizing the Promise of Parity Legislation for Mental Health. JAMA Psychiatry, 2017, 74, 117.	11.0	12
66	Care for the Vulnerable vs. Cash for the Powerful — Trump's Pick for HHS. New England Journal of Medicine, 2017, 376, 103-105.	27.0	12
67	Uninsured by Choice? A choice experiment on long term care insurance. Journal of Economic Behavior and Organization, 2020, 173, 422-434.	2.0	12
68	Price Indexes for Medical Care Goods and Services. , 0, , 141-198.		12
69	Medical Resource Use and Cost of Venlafaxine or Tricyclic Antidepressant Therapy. Pharmacoeconomics, 1999, 15, 495-505.	3.3	11
70	Government Commitment And Regulation Of Prescription Drugs. Health Affairs, 2003, 22, 46-48.	5.2	11
71	ECONOMIC INCENTIVES AND CONTRACTS: THE USE OF PSYCHOTROPIC MEDICATIONS. Contemporary Economic Policy, 2008, 26, 49-72.	1.7	11
72	Decline In New Starts Of Psychotropic Medications During The COVID-19 Pandemic. Health Affairs, 2021, 40, 904-909.	5.2	11

#	Article	IF	CITATIONS
73	Regulated Medicare Advantage And Marketplace Individual Health Insurance Markets Rely On Insurer Competition. Health Affairs, 2017, 36, 1578-1584.	5.2	9
74	The Evolution of Supply and Demand in Markets for Generic Drugs. Milbank Quarterly, 2021, 99, 828-852.	4.4	9
75	Biosimilar competition: Early learning. Health Economics (United Kingdom), 2022, 31, 647-663.	1.7	9
76	The Evolving Private Psychiatric Inpatient Market. Journal of Behavioral Health Services and Research, 2011, 38, 122-131.	1.4	8
77	Customization in prescribing for bipolar disorder. Health Economics (United Kingdom), 2012, 21, 653-668.	1.7	8
78	Using Shared Savings to Foster Coordinated Care for Dual Eligibles. New England Journal of Medicine, 2013, 368, 404-405.	27.0	8
79	MEASURING ADVERSE SELECTION IN MANAGED HEALTH CARE. , 2017, , 29-57.		8
80	Behavioral Health Parity Efforts in the US. JAMA - Journal of the American Medical Association, 2020, 324, 447.	7.4	8
81	Addressing the Risk of Medicare Trust Fund Insolvency. JAMA - Journal of the American Medical Association, 2021, 325, 341.	7.4	8
82	Treatment Price Indexes for Acute Phase Major Depression. , 0, , 463-505.		8
83	Mental Health In The Mainstream Of Health Care. Health Affairs, 2007, 26, 1539-1541.	5.2	7
84	Generic Drug Policy and Suboxone to Treat Opioid Use Disorder. Journal of Law, Medicine and Ethics, 2019, 47, 43-53.	0.9	7
85	Special Section on Implications of CATIE: Policy Toward Second-Generation Antipsychotic Drugs: A Cautionary Note. Psychiatric Services, 2008, 59, 521-522.	2.0	6
86	Work Requirements in Medicaid for People With Mental Illnesses and Substance Use Disorders. Psychiatric Services, 2018, 69, 626-627.	2.0	6
87	Assessing the long-term effects of Basic Medical Insurance on catastrophic health spending in China. Health Policy and Planning, 2022, 37, 747-759.	2.7	6
88	DEMAND RESPONSE TO COST SHARING UNDER MANAGED HEALTH CARE. Contemporary Economic Policy, 2009, 27, 1-15.	1.7	5
89	Reflections on the Mental Health Parity and Addiction Equity Act After 10 Years. Milbank Quarterly, 2018, 96, 615-618.	4.4	5
90	Evaluating selection out of health plans for medicaid beneficiaries with substance abuse. Journal of Behavioral Health Services and Research, 2003, 30, 78-92.	1.4	4

#	Article	IF	CITATIONS
91	Was Part D a Giveaway to the Pharmaceutical Industry?. Inquiry (United States), 2007, 44, 15-25.	0.9	4
92	Demand-Side Factors Associated with the Purchase of Long-Term Care Insurance. Forum for Health Economics and Policy, 2016, 19, 23-43.	0.8	4
93	The Price to Consumers of Generic Pharmaceuticals: Beyond the Headlines. Medical Care Research and Review, 2021, 78, 585-590.	2.1	4
94	The Nature of Pharmaceutical Competition: Implications for Antitrust Analysis. International Journal of the Economics of Business, 2015, 22, 301-343.	1.7	3
95	Friction in the Path to Use of Biosimilar Drugs. New England Journal of Medicine, 2018, 378, 2147-2148.	27.0	3
96	Medicare Drug Prices and the Deficit. New England Journal of Medicine, 2011, 365, 1657-1659.	27.0	2
97	Economics and the Transformation of the Mental Health System. Journal of Health Politics, Policy and Law, 2016, 41, 541-558.	1.9	2
98	Market Concentration and Potential Competition in Medicare Advantage. Issue Brief (Commonwealth) Tj ETQq0	0 0 rgBT /	Overlock 10
99	Evaluating Selection Out of Health Plans for Medicaid Beneficiaries with Substance Abuse. Journal of Behavioral Health Services and Research, 2003, 30, 78???92.	1.4	1
100	Together4Health: Integrating Care for Vulnerable Populations. American Journal of Psychiatric Rehabilitation, 2015, 18, 105-127.	0.7	1
101	Changing Medicare's Protected Classes: History, Mistrust, and Budgets in the Prescription Drug Market. Psychiatric Services, 2019, 70, 858-859.	2.0	1
102	The Trump Administration's Actions to Address the Opioids Public Health Crisis–Reply. JAMA Psychiatry, 2019, 76, 101.	11.0	1
103	Behavioral health carveâ€outs : Do they impede access or prioritize the neediest?. Health Services Research, 2021, 56, 802-804.	2.0	1
104	Making Choice and Competition Work in Individual Insurance in Health Reform Proposals. Issue Brief (Commonwealth Fund), 2019, 2019, 1-11.	0.9	1
105	What policies the US Food and Drug Administration should pursue in response to the addiction and overdose crisis. Addiction, 2022, 117, 1198-1199.	3.3	1

106	Toward Greater Accountability in Mental Health Care. Psychiatric Services, 2023, 74, 182-187.	2.0	1
107	Talbott and Financing Policy: Reducing Fragmentation. Psychiatric Services, 2004, 55, 1150-1151.	2.0	0

108An Analysis of Price Discrimination in Brand Name Drug Wholesaling. International Journal of the<br/>Economics of Business, 2007, 14, 299-315.1.70

#	Article	IF	CITATIONS
109	Overturning the ACA's Medicaid Expansion Would Likely Decrease Low-Income, Reproductive-Age Women's Healthcare Spending and Utilization. Inquiry (United States), 2020, 57, 004695802098146.	0.9	0
110	Jobs for People With Mental Health Conditions: Trends and Prospects. Psychiatric Services, 2021, 72, 143-147.	2.0	0
111	Our Other Epidemic: Addiction. JAMA Health Forum, 2021, 2, e210273.	2.2	0
112	Depression in primary care: quality improvement and economics. Managed Care, 2008, 17, 22-4; discussion 25-6.	0.3	0
113	COMMENTARY: Medicaid Expansion and Mental Health Care and Coverage. Journal of Mental Health Policy and Economics, 2021, 24, 97-99.	0.6	0